|View printer-friendly version|
Covalon’s IV Clear™ is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most commonly associated blood stream infection bacteriai and its skin sparing silicone adhesive will not cause adhesive related skin injury or pain during dressing changesii.
“Our presence at ONS is a result of an increasing number of U.S.
hospital systems inquiring about, trialing or making IV Clear the
dressing of choice for their oncology patients” said
ONS is a professional association of more than 39,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care.
“To any nurse that has ever said that there has to be something better, I encourage you to stop by our booth for a demonstration of the positive difference that IV Clear can make to an oncology patient’s treatment journey.” said Hands.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
i A Laboratory Study of the Synergistic Effect of
Chlorhexidine and Silver, Blom,
ii A Human Repeat Patch Test Study, DiTizio et al. http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters